PT  - JOURNAL ARTICLE
AU  - Alupo, Patricia
AU  - Mugenyi, Levicatus
AU  - Katagira, Winceslaus
AU  - Alex, Kayongo
AU  - Joanitah, Nalunjogi
AU  - Siddharthan, Trishul
AU  - Hurst, John R
AU  - Kirenga, Bruce
AU  - Jones, Rupert
TI  - Characteristics and phenotypes of a COPD cohort in Uganda
AID  - 10.1101/2023.05.11.23289559
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.05.11.23289559
4099  - http://medrxiv.org/content/early/2023/05/15/2023.05.11.23289559.short
4100  - http://medrxiv.org/content/early/2023/05/15/2023.05.11.23289559.full
AB  - Introduction Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous condition with varied clinical and pathophysiologic characteristics. Although there is increasing evidence that COPD in low- and middle-income countries may have different clinical characteristics from that in high income countries, little is known about COPD phenotypes in these settings. We describe the clinical characteristics and risk factor profile of a COPD population in Uganda.Methods We cross sectionally analyzed the baseline clinical characteristics of 323 COPD patients aged 30 years and above who were attending two national referral outpatient facilities in Kampala, Uganda between July 2019 and March 2021. Logistic regression was used to determine factors associated with spirometric disease severity.Results The median age was 62 years; 51.1% females; 93.5% scored CAT >10; 63.8% mMRC >2; 71.8% had wheezing; 16.7% HIV positive; 20.4% had a history of pulmonary tuberculosis; 50% with blood eosinophilic count >3%, 51.7% had 3 or more exacerbations in the past year. Greater severity by GOLD stage was inversely related to age, (aOR=0.95, 95%CI=0.92, 0.97), and obesity compared to underweight (aOR=0.25, 95%CI=0.07, 0.82). Regarding clinical factors, more severe airflow obstruction was associated with SPO2<93% (aOR=3.79, 95%CI=2.05, 7.00), mMMRC≥2 (aOR=2.21, 95%CI=1.08, 4.53), and a history of severe exacerbations (aOR=2.64, 95%CI=1.32, 5.26).Conclusion COPD patients in this population had specific characteristics and risk factor profiles including HIV and TB meriting tailored preventative approaches. Further studies are needed to better understand the pathophysiological mechanisms at play and the therapeutic implications of these findings.Key messagesWhat is already known on this topic.COPD is a heterogeneous condition with the greatest burden in LMICs yet there is limited understanding of disease characteristics in this setting.What this study addsA cohort of patients with COPD recruited in hospital clinics in Uganda showed a high burden of disease with frequent exacerbations – 86% were GOLD category D. The cohort had a high exposure to biomass smoke and only 38% were past or present smokers.How this study might affect research, practice, or policyThere is need for more research into effective strategies to prevent and treat COPD in LMICs - it cannot be assumed that guidelines derived in high-income countries will apply.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by GSKAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committees of Mulago National Referral Hospital gave approval for this work The Ethics committee of Uganda National Council of Science and Technology gave approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reseaonable request to the authors